These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31608799)

  • 1. Pharmacodynamic comparison of low-dose ticagrelor to low-dose prasugrel in patients with prior myocardial infarction: the ALTIC-2 study.
    Alexopoulos D; Sfantou D; Lianos I; Pappas C; Revela I; Triantafyllidi H; Ikonomidis I
    Platelets; 2020 Aug; 31(6):812-814. PubMed ID: 31608799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y
    Franchi F; Rollini F; Faz G; Rivas JR; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Fahmi K; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Baber U; Mehran R; Jennings LK; Bass TA; Angiolillo DJ
    J Am Heart Assoc; 2020 Apr; 9(8):e015865. PubMed ID: 32306797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of cessation of 2nd generation P
    Witberg G; Bathish J; Bental T; Leshem-Lev D; Assali A; Kornowski R; Lev E
    J Thromb Thrombolysis; 2018 Oct; 46(3):351-358. PubMed ID: 29922880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased platelet inhibition after switching from prasugrel to low-dose ticagrelor in Japanese patients with prior myocardial infarction.
    Tateishi K; Saito Y; Kitahara H; Nakayama T; Fujimoto Y; Kobayashi Y
    J Cardiol; 2020 May; 75(5):473-477. PubMed ID: 31718953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
    Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
    J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
    Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
    Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.
    Eisen A; Lerman-Shivek H; Perl L; Rechavia E; Leshem-Lev D; Zemer-Wassercug N; Dadush O; Kazum S; Codner P; Kornowski R; Lev EI
    J Thromb Thrombolysis; 2015 Jul; 40(1):70-5. PubMed ID: 25481810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.
    Motovska Z; Hlinomaz O; Kala P; Hromadka M; Knot J; Varvarovsky I; Dusek J; Jarkovsky J; Miklik R; Rokyta R; Tousek F; Kramarikova P; Svoboda M; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
    J Am Coll Cardiol; 2018 Jan; 71(4):371-381. PubMed ID: 29154813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial.
    Ueki Y; Häner JD; Losdat S; Gargiulo G; Shibutani H; Bär S; Otsuka T; Kavaliauskaite R; Mitter VR; Temperli F; Spirk D; Stortecky S; Siontis GCM; Valgimigli M; Windecker S; Gutmann C; Koskinas KC; Mayr M; Räber L
    Thromb Haemost; 2024 Jun; 124(6):517-527. PubMed ID: 37595625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Clinical Outcomes Between Ticagrelor and Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction　- Results From the Korea Acute Myocardial Infarction Registry-National Institutes of Health.
    Kim MC; Jeong MH; Sim DS; Hong YJ; Kim JH; Ahn Y; Ahn TH; Seung KB; Choi DJ; Kim HS; Gwon HC; Seong IW; Hwang KK; Chae SC; Hur SH; Cha KS; Oh SK; Chae JK;
    Circ J; 2018 Jun; 82(7):1866-1873. PubMed ID: 29643279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
    Motovska Z; Hlinomaz O; Miklik R; Hromadka M; Varvarovsky I; Dusek J; Knot J; Jarkovsky J; Kala P; Rokyta R; Tousek F; Kramarikova P; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
    Circulation; 2016 Nov; 134(21):1603-1612. PubMed ID: 27576777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
    Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
    BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Data of Prasugrel vs. Ticagrelor in Acute Myocardial Infarction: Results from the RENAMI Registry.
    De Filippo O; Cortese M; D Ascenzo F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Montefusco A; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Rinaldi M
    Am J Cardiovasc Drugs; 2019 Aug; 19(4):381-391. PubMed ID: 31030413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
    Máchal J; Hlinomaz O
    Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
    Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment-Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial.
    van der Hoeven NW; Janssens GN; Everaars H; Nap A; Lemkes JS; de Waard GA; van de Ven PM; van Rossum AC; Escaned J; Mejia-Renteria H; Ten Cate TJF; Piek JJ; von Birgelen C; Valgimigli M; Diletti R; Riksen NP; Van Mieghem NM; Nijveldt R; van Leeuwen MAH; van Royen N
    J Am Heart Assoc; 2020 Mar; 9(5):e014411. PubMed ID: 32122216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.